Immunotherapies targeting the programmed cell death 1 (PD-1)/programmed death ligand 1 (PD-L1) have shown great promise for a subset of patients with non-small cell lung cancer (NSCLC).
However, safe and robust combination therapies are still needed to bring the benefit to broader patient populations.
